<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78995</article-id><article-id pub-id-type="doi">10.7554/eLife.78995</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Type 1 piliated uropathogenic <italic>Escherichia coli</italic> hijack the host immune response by binding to CD14</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-275304"><name><surname>Tomasek</surname><given-names>Kathrin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-257243"><name><surname>Leithner</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275305"><name><surname>Glatzova</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257241"><name><surname>Lukesch</surname><given-names>Michael Sebastian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-232760"><name><surname>Guet</surname><given-names>Calin C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6220-2052</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-72354"><name><surname>Sixt</surname><given-names>Michael</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6620-9179</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><institution>Institute of Science and Technology Austria</institution>, <addr-line><named-content content-type="city">Klosterneuburg</named-content></addr-line>, <country>Austria</country></aff><aff id="aff2"><institution>VALANX Biotech GmbH</institution>, <addr-line><named-content content-type="city">Klosterneuburg</named-content></addr-line>, <country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-172210"><name><surname>Zanoni</surname><given-names>Ivan</given-names></name><role>Reviewing editor</role><aff><institution>Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>kathrin.tomasek@epfl.ch</email> (KT);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>calin.guet@ist.ac.at</email> (CG);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>sixt@ist.ac.at</email> (MS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>07</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e78995</elocation-id><history><date date-type="received"><day>26</day><month>03</month><year>2022</year></date><date date-type="accepted"><day>19</day><month>07</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Tomasek et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Tomasek et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78995-v1.pdf"/><abstract><p>A key attribute of persistent or recurring bacterial infections is the ability of the pathogen to evade the host's immune response. Many <italic>Enterobacteriaceae</italic> express type 1 pili, a pre-adapted virulence trait, to invade host epithelial cells and establish persistent infections. However, the molecular mechanisms and strategies by which bacteria actively circumvent the immune response of the host remain poorly understood. Here, we identified CD14, the major co-receptor for lipopolysaccharide detection, on mouse dendritic cells as a binding partner of FimH, the protein located at the tip of the type 1 pilus of <italic>Escherichia coli</italic>. The FimH amino acids involved in CD14 binding are highly conserved across pathogenic and non-pathogenic strains. Binding of the pathogenic strain CFT073 to CD14 reduced dendritic cell migration by overactivation of integrins and blunted expression of co-stimulatory molecules by overactivating the NFAT pathway, both rate-limiting factors of T cell activation. This response was binary at the single cell level, but averaged in larger populations exposed to both piliated and non-piliated pathogens, presumably via the exchange of immunomodulatory cytokines. While defining an active molecular mechanism of immune evasion by pathogens, the interaction between FimH and CD14 represents a potential target to interfere with persistent and recurrent infections, such as urinary tract infections or Crohn's disease.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>CoG 724373</award-id><principal-award-recipient><name><surname>Sixt</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>FWF P29911</award-id><principal-award-recipient><name><surname>Sixt</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Kathrin Tomasek, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections&quot;).&quot;.</p></fn><fn fn-type="conflict" id="conf3"><p>Michael Sebastian Lukesch, is affiliated with VALANX Biotech GmbH. The author has no financial interests to declare.Is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections&quot;).&quot;.</p></fn><fn fn-type="conflict" id="conf4"><p>Calin C Guet, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections&quot;).&quot;.</p></fn><fn fn-type="conflict" id="conf5"><p>Michael Sixt, is an inventor on patent application 21170193.3 (Methods determining the potential of drug for treating bacterial infections and composition for treating bacterial infections&quot;).&quot;.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments are in accordance with the Austrian law for animal experiments. Permission was granted by the Austrian Federal Ministry of Science, Research and Economy (identification code: BMWFW 66.018/0010-WF/V/3b/2016). Mice were bred and maintained at the local animal facility in accordance IST Austria Ethical Committee or purchased from Charles River and maintained at the local animal facility in accordance with IST Austria Ethical Committee.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data are included in the manuscript. Source data are uploaded with this manuscript.</p></sec><supplementary-material><ext-link xlink:href="elife-78995-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>